Clinical Practice Session
Clinical Trials in Glomerular Diseases: Can We Still Deliver Them? Including the Michelle P. Winn, MD, Endowed Lectureship
October 22, 2026 | 10:30 AM - 12:30 PM
Location: Mile High Ballroom 2, Convention Center
Session Description
The last five years have seen a seismic shift in clinical trial activity in glomerular diseases, with many trials reporting positive results and new drugs being approved. These successes are now challenging how we design and deliver clinical trials in glomerular diseases, as traditional placebo-controlled trial designs are increasingly difficult to implement when multiple approved drugs are available. Is it now time to take stock of recent successes and rethink how we design and deliver clinical trials for adults and children with glomerular diseases? This session reviews current progress, the development of new end points to assess drug efficacy in adults and children, and the U.S. Food and Drug Administration's views on the future of clinical trials in glomerular diseases.
ASN gratefully acknowledges Duke University School of Medicine, the school's Division of Nephrology, and several individuals for support of the Winn Endowed Lectureship.
Learning Objective(s)
- Describe the design of clinical trials in rare glomerular diseases
- Define the end points for drug approval in glomerular diseases
- Discuss the current clinical trial landscape in glomerular diseases
Learning Pathway(s)
- Glomerular Diseases
- Pediatric Nephrology
Moderators
Presentations
- How Has the Clinical Trial Landscape in Glomerular Diseases Changed in the Past Five Years? The Michelle P. Winn, MD, Endowed Lectureship
10:30 AM - 11:00 AM
- How Can We Develop Trial End Points to Facilitate Clinical Trial Delivery in Glomerular Diseases?
11:00 AM - 11:30 AM
- How Do We Involve Children in Glomerular Disease Trials?
11:30 AM - 12:00 PM
- Evolution of the Regulatory Framework for Drug Approvals in Glomerular Diseases: What's Next?
12:00 PM - 12:30 PM